{"clinical_study": {"@rank": "256", "required_header": {"download_date": "ClinicalTrials.gov processed this data on April 02, 2020", "link_text": "Link to the current ClinicalTrials.gov record.", "url": "https://clinicaltrials.gov/show/NCT04252274"}, "id_info": {"org_study_id": "DACO-nCoV", "nct_id": "NCT04252274"}, "brief_title": "Efficacy and Safety of Darunavir and Cobicistat for Treatment of Pneumonia Caused by 2019-nCoV", "acronym": "DACO-nCoV", "official_title": "Efficacy and Safety of Darunavir and Cobicistat for Treatment of Pneumonia Caused by 2019-nCoV", "sponsors": {"lead_sponsor": {"agency": "Shanghai Public Health Clinical Center", "agency_class": "Other"}}, "source": "Shanghai Public Health Clinical Center", "oversight_info": {"has_dmc": "No", "is_fda_regulated_drug": "No", "is_fda_regulated_device": "No", "is_us_export": "No"}, "brief_summary": {"textblock": "The study aims to evaluate the efficacy and safety of darunavir and cobistastat in the\n      treatment of pneumonia caused by the 2019 novel coronavirus"}, "detailed_description": {"textblock": "There is no vaccine or antiviral treatment for human coronavirus, so this study aims to\n      evaluate the efficacy and safety of darunavir and cobistastat in the treatment of pneumonia\n      caused by the 2019 novel coronavirus."}, "overall_status": "Recruiting", "start_date": {"@type": "Actual", "#text": "January 30, 2020"}, "completion_date": {"@type": "Anticipated", "#text": "December 31, 2020"}, "primary_completion_date": {"@type": "Anticipated", "#text": "August 31, 2020"}, "phase": "Phase 3", "study_type": "Interventional", "has_expanded_access": "No", "study_design_info": {"allocation": "Randomized", "intervention_model": "Parallel Assignment", "primary_purpose": "Treatment", "masking": "None (Open Label)"}, "primary_outcome": {"measure": "The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 7", "time_frame": "7 days after randomization"}, "secondary_outcome": [{"measure": "The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 3", "time_frame": "3 days after randomization"}, {"measure": "The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 5", "time_frame": "5 days after randomization"}, {"measure": "Number of participants with treatment-related adverse events as assessed by CTCAE v5.0", "time_frame": "14 days after randomization"}, {"measure": "The critical illness rate of subjects at weeks 2", "time_frame": "14 days after randomization", "description": "The diagnosis of critical illness case was based on the notice on printing and distributing the diagnosis and treatment plan of pneumonia with new coronavirus infection (trial version 4) made by National Health Commission of the People's Republic of China."}, {"measure": "The mortality rate of subjects at weeks 2", "time_frame": "14 days after randomization"}], "number_of_arms": "2", "enrollment": {"@type": "Anticipated", "#text": "30"}, "condition": ["Pneumonia, Pneumocystis", "Coronavirus"], "arm_group": [{"arm_group_label": "Darunavir, Cobicistat and conventional treatments", "arm_group_type": "Experimental", "description": "After randomization, subjects take darunavir and cobicistat one tablet per day for 5 days, also take conventional treatments."}, {"arm_group_label": "Conventional treatments", "arm_group_type": "No Intervention", "description": "After randomization, subjects take conventional treatments without darunavir and cobicistat."}], "intervention": {"intervention_type": "Drug", "intervention_name": "Darunavir and Cobicistat", "description": "Subjects take darunavir and cobicistat one tablet per day for 5 days, also take conventional treatments", "arm_group_label": "Darunavir, Cobicistat and conventional treatments"}, "eligibility": {"criteria": {"textblock": "Inclusion Criteria:\n\n          -  The participants were diagnosed as pneumonia caused by 2019-nCoV, according to the\n             notice on printing and distributing the diagnosis and treatment plan of pneumonia with\n             new coronavirus infection (trial version 4 or update version) made by National Health\n             Commission of the People's Republic of China.\n\n          -  Written the informed consent\n\n        Exclusion Criteria:\n\n          -  Hypersensitivity to darunavir, colibrestat, or any excipients\n\n          -  Patients with severe liver injury (Child-Pugh Class C)\n\n          -  Concomitant medications that are highly dependent on CYP3A clearance, and the elevated\n             plasma concentrations are associated with serious or life-threatening events.\n\n          -  Subjects were considered to be unable to complete the study, or not suitable for the\n             study by researchers\n\n        Exit criteria:\n\n          -  Subjects asked to withdraw the study\n\n          -  Subject will benefit if withdraw according to researchers' suggestions"}, "gender": "All", "minimum_age": "N/A", "maximum_age": "N/A", "healthy_volunteers": "No"}, "overall_contact": {"last_name": "Hongzhou Lu, Ph.D", "phone": "+86-021-37990333", "phone_ext": "3222", "email": "luhongzhou@fudan.edu.cn"}, "overall_contact_backup": {"last_name": "Hongzhou Lu, PI", "phone": "+86-021-37990333", "phone_ext": "3222", "email": "luhongzhou@fudan.edu.cn"}, "location": [{"facility": {"name": "Shanghai Public Health Clinical Center", "address": {"city": "Shanghai", "state": "Shanghai", "zip": "201508", "country": "China"}}, "status": "Recruiting", "contact": {"last_name": "Hongzhou Lu", "phone": "008602137990333", "phone_ext": "3222"}}, {"facility": {"name": "Shanghai Public Health Clinical Center", "address": {"city": "Shanghai", "state": "Shanghai", "country": "China"}}, "status": "Recruiting", "contact": {"last_name": "Hongzhou Lu, PI", "phone": "+86-021-37990333", "phone_ext": "3222", "email": "luhongzhou@fudan.edu.cn"}}], "location_countries": {"country": "China"}, "verification_date": "March 2020", "study_first_submitted": "January 29, 2020", "study_first_submitted_qc": "January 31, 2020", "study_first_posted": {"@type": "Actual", "#text": "February 5, 2020"}, "last_update_submitted": "March 3, 2020", "last_update_submitted_qc": "March 3, 2020", "last_update_posted": {"@type": "Actual", "#text": "March 4, 2020"}, "responsible_party": {"responsible_party_type": "Principal Investigator", "investigator_affiliation": "Shanghai Public Health Clinical Center", "investigator_full_name": "Hongzhou Lu", "investigator_title": "professor"}, "keyword": ["Pneumonia", "2019-new coronavirus", "Darunavir", "Cobicistat"], "condition_browse": {"mesh_term": ["Pneumonia, Pneumocystis", "Coronavirus Infections", "Pneumonia"]}, "intervention_browse": {"mesh_term": ["Darunavir", "Cobicistat"]}}}